S
Solid Biosciences Inc. (SLDB)
NMS – Real vaqt narxi. Valyuta: USD
7.72
+0.04 (0.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
7.68
-0.04 (-0.52%)
Bozordan keyin: May 12, 2026, 7:19 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
7.72
+0.04 (0.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
7.68
-0.04 (-0.52%)
Bozordan keyin: May 12, 2026, 7:19 PM EDT
Solid Biosciences Inc. Amerika Qo'shma Shtatlarida neuromuskulyar va yurak kasalliklari uchun terapiyalarni ishlab chiqadi. Kompaniyaning asosiy mahsulot nomzodi SGT-003 bo'lib, u Duchenne mushak distrofiyasini davolash uchun 1/2-bosqichda. Kompaniya Friedreich ataksiyasini davolash uchun SGT-212ni ishlab chiqadi, u 1b-bosqich klinik sinovda; katexolaminergik polimorfik qorincha taxikardiyasini davolash uchun SGT-501, u preklinik bosqichda; TNNT2 vositachiligidagi dilatatsion kardiomiopatiyani davolash uchun SGT-601, u preklinik bosqichda; BAG3 vositachiligidagi dilatatsion kardiomiopatiyani davolash uchun SGT-401, u preklinik bosqichda; RBM20 geni mutatsiyalari bilan tavsiflangan noyob irsiy kasallikni davolash uchun SGT-701, u kashfiyot bosqichida; va yurak va boshqa kasalliklarni davolash uchun boshqa dorilar. Bundan tashqari, kompaniya kapsid kutubxonalari; promotorlar, UTRlar va intronlar kabi genetik regulyatorlar; immunomodulyatsiya texnologiyalari; ishlab chiqarish tozaligi; va bir kapsidga bir nechta transgenlarni qadoqlash texnologiyasi bo'lgan ikki genli ekspressiya kabi platforma texnologiyalarini ishlab chiqish bilan shug'ullanadi. Kompaniya Ultragenyx Pharmaceutical Inc. bilan hamkorlik va litsenziya shartnomasiga; va Vashington universiteti, Missuri universiteti, Florida universiteti va ICS Maugeri S.p.A. bilan litsenziya shartnomasiga ega. Solid Biosciences Inc. 2013 yilda ro'yxatga olingan va shtab-kvartirasi Charlestonda, Massachusets shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Gabriel Brooks M.D. | Chief Medical Officer |
| Dr. Jessie Hanrahan Ph.D. | Chief Regulatory & Preclinical Operations Officer |
| Mr. Alexander G. Cumbo | President, CEO & Director |
| Mr. David Tyronne Howton Jr., J.D. | COO & Secretary |
| Mr. Ian F. Smith A.C.A., C.P.A. | Executive Chair |
| Mr. Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 10-Q | sldb-20260331.htm |
| 2026-04-23 | DEF 14A | sldb-20260422.htm |
| 2026-04-23 | ARS | ars_2025.pdf |
| 2026-04-10 | 8-K | sldb-20260410.htm |
| 2026-03-27 | CORRESP | filename1.htm |
| 2026-03-19 | S-8 | sldb-20260318.htm |
| 2026-03-19 | S-3 | d125122ds3.htm |
| 2026-03-12 | 8-K | sldb-20260311.htm |
| 2026-03-06 | 8-K | d81855d8k.htm |
| 2025-11-03 | 10-Q | sldb-20250930.htm |
| Mr. Kevin Tan C.F.A. | CFO & Treasurer |
| Mr. Paul Herzich | Chief Technology Officer |
| Ms. Annie Ganot | Co-Founder & VP of Patient Advocacy |
| Ms. Nicole Anderson | Senior Director of Investor Relations & Corporate Communications |